Kintara Therapeutics (KTRA)

Kintara Therapeutics (KTRA) Income Statement


Kintara Therapeutics Income Statement

Last quarter (Q3 2023), Kintara Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Kintara Therapeutics's net income was $-3.27M. See Kintara Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 22Jun 21Jun 20Jun 19Jun 18
Total Revenue
--$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ 5.22M$ 22.67M$ 21.57M$ 8.14M$ 8.40M$ 11.17M
Operating Income
$ -12.18M$ -22.67M$ -21.57M$ -8.14M$ -8.40M$ -11.17M
Net Non Operating Interest Income Expense
$ 11.00K-$ -120.00K$ 75.00K$ 60.70K$ 33.24K
Other Income Expense
$ 1.00K$ -16.72M$ -16.61M$ -1.06M$ 289.57K$ 3.11K
Pretax Income
$ -12.16M$ -22.66M$ -38.30M$ -9.13M$ -8.05M$ -11.14M
Tax Provision
-$ -196.00K----
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -12.17M$ -25.13M$ -41.50M$ -9.14M$ -8.13M$ -11.31M
Basic EPS
$ -11.04$ -0.52$ -1.60$ -0.87$ -3.16$ -5.42
Diluted EPS
$ -8.94$ -0.52$ -1.60$ -0.87$ -3.16$ -5.42
Basic Average Shares
$ 6.05M$ 48.70M$ 25.89M$ 10.44M$ 2.57M$ 2.09M
Diluted Average Shares
$ 4.40M$ 48.70M$ 25.89M$ 10.44M$ 2.57M$ 2.09M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 5.22M$ 22.67M$ 21.57M$ 8.14M$ 8.40M$ 11.17M
Net Income From Continuing And Discontinued Operation
$ -12.16M$ -22.66M$ -38.30M$ -9.13M$ -8.05M$ -11.14M
Normalized Income
$ -5.45M-$ -21.69M$ -8.07M$ -8.34M$ -11.14M
Interest Expense
--$ 26.00K---
$ -12.18M$ -22.66M$ -38.27M$ -8.14M$ -8.40M$ -11.17M
$ -9.98M$ -22.60M$ -38.24M$ -8.13M$ -8.38M$ -11.15M
Currency in USD

Kintara Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis